Review Services
Central Oncology Review
Specialized Institutional Review Board (IRB) Services for an Evolving Regulatory Landscape
Aligned with the needs of the growing and increasingly complex field of oncology, Advarra provides the robust human subject protections review cancer research institutions expect.
Key Features
- Accelerated study startup
- Dedicated point of contact for every study
- Faster turnaround times come standard
- Automated data and document flow
Advarra is the #1 Central IRB for Oncology
100% of Oncology Indications Reviewed
Specialized expertise in pediatrics, targeted therapies, cell and gene therapy, device, complex protocol design, and more.
Dedicated Point of Contact for Every Study
Our dedicated support staff understand your protocol and program, so they can be more responsive to your questions and provide faster answers.
IRB Submission is NOT a “Black Box”
Get instant transparency every step of the way with access to real-time review statuses. Additionally, the platform saves submission data to reduce redundant work and lower administrative burden.
Faster Turnaround Times Come Standard
Advarra has 7x more IRB meetings per week with oncology expertise – no waiting for a dedicated meeting. All clients experience rapid timelines and premium service at no additional cost.
The Only eIRB System to Automate Data and Document Flow
Save time, reduce data entry errors, and improve inspection readiness with documents and data delivered straight from the eIRB system to the electronic investigator site file (eISF) and electronic trial master file (eTMF) systems.
Board Members Include Active Clinicians and Researchers
We have 400+ oncology experts supporting reviews. Our members offer real-world and academic perspectives and have experience with the latest therapeutic innovations and specialized modalities, ensuring you receive the most comprehensive review.
2x More Oncology Studies Reviewed Than Any Other Independent IRB
Cancer Types
Antibody-drug conjugates, bladder/urinary tract cancer, blood and lymph cancers, breast cancer, cancer diagnostics, cervical cancer, colon/colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, sarcoma, and skin cancer.
Therapies
Chemotherapy, gene therapy, immunotherapy (e.g., CAR-T cell therapy), palliative care management, precision medicine (e.g., basket, umbrella, and targeted therapy trials), and radiotherapy.
Specialized Areas
Complex protocol designs, pediatric trials, device trials, and oncology-specific diagnostics.
